Inotiv (NASDAQ:NOTV) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Inotiv (NASDAQ:NOTV) posted its quarterly earnings data on Wednesday. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative net margin of 22.10% and a negative return on equity of 15.86%.

Inotiv Trading Down 3.4 %

Shares of NOTV stock traded down $0.14 on Friday, hitting $3.79. The company had a trading volume of 199,848 shares, compared to its average volume of 647,940. Inotiv has a twelve month low of $1.23 and a twelve month high of $11.42. The company has a debt-to-equity ratio of 2.29, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market cap of $98.45 million, a P/E ratio of -0.90 and a beta of 3.58. The stock’s 50-day moving average is $4.43 and its two-hundred day moving average is $2.80.

Insider Buying and Selling

In other news, CEO Robert Jr. Leasure sold 22,700 shares of Inotiv stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $4.15, for a total value of $94,205.00. Following the completion of the transaction, the chief executive officer now directly owns 1,030,209 shares of the company’s stock, valued at approximately $4,275,367.35. This trade represents a 2.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nigel Brown acquired 7,500 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average cost of $4.26 per share, for a total transaction of $31,950.00. Following the completion of the purchase, the director now directly owns 65,537 shares in the company, valued at $279,187.62. This trade represents a 12.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 71,029 shares of company stock valued at $314,248 and have sold 26,872 shares valued at $112,854. 7.80% of the stock is owned by insiders.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.